Phenotypes of chronic obstructive pulmonary disease and approaches to treatment of acute exacerbations of COPD in Russian Federation: results of NIS CLOUD non-interventional study

The objective of this study was to describe pharmacological management (including different schemes of glucocorticoid therapy) of patients with severe and very severe COPD, management of acute exacerbation of COPD (AECOPD) and causes of change in the therapy.

Methods. This was an observational multicenter descriptive study. The study involved 1,029 patients admitted to a hospital due to AECOPD. Demographic, social and economic data and patients’ distribution to clinical phenotypes according to the Czech classification, history of COPD, serious comorbidity, pharmacotherapy for COPD, smoking status, occupational history, health status and quality of life were analyzed.

Results. Phenotypes of chronic bronchitis and of frequent exacerbator were the most common. There were 795 patients (77.26%) with stage 3 COPD and 234 patients (22.66%) with stage 3 COPD in the population involved. About 95% patients were treated in line with GOLD, 2014. Three months after hospital discharge, therapy with inhaled corticosteroids (ICS) was changed in 89 patients (10.45%), mostly due to an acute exacerbation of COPD (about 29%), followed by a high cost of the drugs (25.4%) and non-reimbursable drugs (21%).

Conclusion. Pharmacological therapy was guideline-adherent in majority of patients with severe and very severe. ICS as single therapy or in fixed combinations with long-acting beta-agonists comprised a significant part of treatment in those patients. Therapy was change during 12 months after hospital discharge in 59% of patients.

1. Avdeev S.N. Is it possible to improve prognosis in patients with chronic obstructive pulmonary disease? Pul’monologiya. 2015; 25 (4): 469–476. DOI: 10.18093/0869-0189-2015-25-4-469-476 (in Russian).

2. Alekseenko S.N., Drobot E.V. Prevention of diseases. Moscow: Akademiya Estestvoznaniya; 2015 (in Russian).

3. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Russian Respiratory Society. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Pul'monologiya. 2014; (3): 15–54. 2014; 3: 15–54. DOI: 10.18093/0869-0189-2014-0-3-15-54 (in Russian).

4. Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; (13): 183–187. DOI: 10.2147/COPD.S153770.

5. Nedogoda S.V., Tsoma V.V., Ledyayeva A.A. et al. Current abilities for therapy of COPD in Russia: from guidelines to the real-life practice. Effektivnaya farmakoterapiya. 2017; (14): 24–32 (in Russian).

6. Global Initiative for Chronic Obstructive Lung Disease. Updated 2016. Available at: http://www.doctorbeketov.ru/data/documents/GOLD-2016-EU-Global-Strategy.pdf

7. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; (9): 963–974. DOI: 10.2147/COPD.S67283.

8. World Health Organization. Global status report on noncommunicable diseases. 2014. Available at: http://www.who.int/nmh/publications/ncd-status-report-2014/en/

9. Vanfleteren L.E., Franssen F.M., Wesseling G., Wouters E.F. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir. Med. 2012; 106 (6): 871–874. DOI: 10.1016/j.rmed.2012.01.008.

10. Aisanov Z. R., Avdeev S. N., Arkhipov V. V. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Russian Pulmonology. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).

11. Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med. 2006; 5 (5): 343–349.

12. Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI: 10.1164/rccm.200707-973OC.

13. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121 (5): 1434–1440. DOI: 10.1378/chest.121.5.1434.

14. Landis S.H., Muellerova H., Mannino D.M. et al. Continuing to confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; (9): 597–611. DOI: 10.2147/COPD.S61854.

15. Arkhipov V.V., Arkhipova D.E., Stukalina E.Yu. et al. Prevalence and description of certain phenotypes of chronic obstructive pulmonary disease in Russian Federation and therapeutic approaches. Prakticheskaya pul’monologiya. 2016; (3): 20–25 (in Russian).

16. Arkhipov V., Arkhipova D., Miravitlles M. et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 3255–3262. DOI: 10.2147/COPD.S142997.

17. Koblizek V., Chlumsky J., Zindr V. et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 2013; 157 (2): 189–201. DOI: 10.5507/bp.2013.039.

18. Palmqvist M., Arvidsson P., Beckman O. et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm. Pharmacol. Ther. 2001; 14 (1): 29–34. DOI: 10.1006/pupt.2000.0260.

19. Lindberg A., Szalai Z., Pullerits T., Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology. 2007; 12 (5): 732–739. DOI: 10.1111/j.1440-1843.2007.01132.x

20. Partridge M.R., Schuermann W., Beckman O. et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther. Adv. Respir. Dis. 2009; 3 (4): 1–11. DOI: 10.1177/1753465809344870.

21. Koblizek V., Milenkovic B., Barczyk. A. et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur. Respir. J. 2017; 49 (5): pii: 1601446. DOI: 10.1183/13993003.01446-2016.